Endocrinology5 Aug 2026
Setmelanotide curbs insatiable hunger in acquired hypothalamic obesityRead article
The Life Science Feed
Deep dives with clinicians, researchers, and industry leaders.
All episodes
Metastatic pancreatic cancer: A new drug could shift your approach
The EMA granted accelerated assessment for an investigational medicine for metastatic pancreatic adenocarcinoma, potentially offering a new option in a difficult disease.
The real reason joint oncology practices need explicit protocols
Running a joint oncology clinic presents unique challenges and benefits, requiring careful navigation of professional boundaries and patient dynamics.
How non-animal models are redefining oncology drug safety
The FDA issued draft guidance to reduce animal testing for oncology drugs, allowing sponsors to use non-animal methods for certain safety and efficacy assessments.
Sitting for Long Stretches Linked to Higher Cancer Mortality Risk
Molecular Profiling Refines Salivary Gland Tumor Diagnosis
ARHGAP36: A new survival predictor for neuroblastoma patients
Jideytro offers new hope for ROS1-positive NSCLC after prior therapy
Forget sterile tumors: Cancers house unique microbiomes
Cancer survival improves. Why are rural outcomes still worsening?
Liver-Directed Treatment Shows Efficacy in Metabolic Dysfunction
A novel liver-directed treatment presented at endo 2026 offers a targeted approach for metabolic dysfunction, addressing a significant unmet clinical need.
TNF emerges as a key node in autoimmune hepatitis, trial shows
An integrative omics approach identified TNF as a central pathogenic driver in autoimmune hepatitis, with a phase IIa trial validating TNF inhibition.
Nearly 1 in 10 With Primary Biliary Cholangitis Have CKD
Chronic kidney disease affects 9.5% of patients with primary biliary cholangitis, with hypertension and older age driving incidence.
EHR data identifies liver transplant patients at high risk of early graft loss
Liver Transplant Studies Retracted Over Organ Harvesting Concerns
Chronic Hepatitis Delta Virus: Why direct viral targeting matters now
Smartphones and Pacemakers: Separating Fact from Electromagnetic Fiction
Modern smartphones pose minimal risk of electromagnetic interference with pacemakers and ICDs, provided a safe distance is maintained.
Severe VT in ischaemic cardiomyopathy: Why current care isn't enough
A case of sustained ventricular tachycardia in ischaemic cardiomyopathy highlights the complexities of managing severe left ventricular systolic dysfunction.
Pulsed Field Ablation: A New Frontier for Atrial Fibrillation?
Pulsed field ablation offers a novel, non-thermal approach to cardiac tissue destruction, leveraging irreversible electroporation for targeted cell death in arrhythmias.
Heart Failure Treatment in 2026: A Clinical Overview
How lipid packing dictates caveolae stability at the plasma membrane
Cardiovascular risk: Why men die earlier, women live sicker
Metabolic Syndrome: Is it accelerating your patients' brain aging?
Metabolic syndrome, affecting one in four adults, significantly accelerates brain aging and increases the risk of cognitive decline, impacting neurovascular health.
Setmelanotide curbs insatiable hunger in acquired hypothalamic obesity
Setmelanotide significantly improved body mass index, hunger, and hyperphagia symptoms in patients with acquired hypothalamic obesity, according to the TRANSCEND trial.
CGM offers tighter glucose control for type 2 diabetes on dialysis
Continuous glucose monitoring (CGM) improves glycemic control in patients with type 2 diabetes undergoing hemodialysis, a population often overlooked in diabetes management.
Your obesity patients deserve more than just weight loss goals
Weekly growth hormone therapy: a safer path to long-term height gains?
Tzield expands its reach: A new option for recently diagnosed pediatric type 1 diabetes
Katie Couric's Transient Global Amnesia: A 'Big, Black Hole' Event
Katie Couric recently described an episode of transient global amnesia, a sudden, temporary loss of memory that can be alarming but is typically benign.
Vitamin C's cognitive promise clashes with new clinical data
Vitamin C supplementation does not improve cognitive function in healthy adults. Advanced MRI reveals previously undetectable MS lesions, while new criteria define profound autism.
Repeated head impacts: What they mean for dementia risk
Repeated blows to the head in contact sports significantly increase the risk of dementia, particularly in former professional athletes.
Beyond screen time: How short videos rewire dopamine pathways
The long shadow of head trauma: sport, CTE, and dementia risk
Chronic Migraine: Is the Gut-Brain Axis the Missing Link?
Multiple MyelomaThe Neutropenic Diet: An Unnecessary Burden for Leukemia and Transplant Patients?
Get the full story10 min readRNR inhibition reverses FLT3i resistance in AML, prolonging survival
Get the full story9 min readAsciminib: A new first-line option for chronic myeloid leukemia?
Get the full story10 min readWhat Is CAR-T Cell Therapy? Mechanism, Approved Indications, and Key Evidence
Get the full story5 min readDonor T-cells prevent CMV complications in blood cancer patients
Get the full story6 min readMAHA Monday: The Rush to Publish and Its Clinical Fallout
Get the full story11 min readLiso-Cel Delivers Durable OS Benefit in R/R LBCL, Redefining Treatment
Get the full story11 min readNew Regimen Confers 'Meaningful' Benefit in Aggressive Lymphoma
Get the full story7 min readFDA Expands Casgevy for Sickle Cell in Children 2 Years and Older
Get the full story8 min readMonoclonal Antibodies May Complicate Transfusion Testing
Get the full story7 min read
Arthritis Rheumatoid
Lung Neoplasms
Drug Resistance MicrobialEHR data flags liver transplant patients at highest risk of post-op complications
Why cardiac amyloidosis diagnoses are surging and what it means for GPs
GLP-1s and lifestyle: a new path to stronger bones?
Ecopipam for Tourette Syndrome: Did it deliver on its promise?
• Aug 28 – 31ERS 2026 • Barcelona, ES 
• Sep 5 – 9EASD 2026 • Milan, IT 
• Sep 28 – Oct 2UEG Week 2026 • Vienna, AT 
• Oct 3 – 7Joint ACTRIMS-ECTRIMS 2026 • Toronto, CA 
• Oct 21 – 23ESMO 2026 • Madrid, ES • Oct 23 – 27AHA 2026 • Chicago, US 
• Nov 7 – 9ACR 2026 • Washington DC, US • Nov 14 – 19ASH 2026 • New Orleans, US • Dec 12 – 15ACC.27 Together With WCC • Houston, US • Apr 10 – 12ESC 2026 • Munich, DE • Aug 28 – 31ERS 2026 • Barcelona, ES • Sep 5 – 9EASD 2026 • Milan, IT • Sep 28 – Oct 2UEG Week 2026 • Vienna, AT • Oct 3 – 7Joint ACTRIMS-ECTRIMS 2026 • Toronto, CA • Oct 21 – 23ESMO 2026 • Madrid, ES • Oct 23 – 27AHA 2026 • Chicago, US • Nov 7 – 9ACR 2026 • Washington DC, US • Nov 14 – 19ASH 2026 • New Orleans, US • Dec 12 – 15ACC.27 Together With WCC • Houston, US • Apr 10 – 12
BostonJun 13 – 16 2026
XLH Adults: Osteomalacia Persists Despite Conventional Therapy
Adults with X-linked hypophosphatemia (XLH) frequently experience persistent osteomalacia, even with conventional phosphate and active vitamin D treatment.
Afirma Molecular Testing: Unique Situations and New Prognostic Development
Afirma molecular testing aids thyroid nodule management, particularly in indeterminate cytology. New prognostic markers enhance risk stratification.
GLP-1 RAs Reduce CV Risk in T2D Via Weight, Glucose Pathways
GLP-1 receptor agonists offer cardiovascular risk reduction in type 2 diabetes through both weight loss and direct glucose-lowering mechanisms.
Defining Hyperphagia Treatment Possibilities in Prader-Willi Syndrome
Clinician and caregiver perspectives highlight the complex challenges and unmet needs in managing hyperphagia in Prader-Willi Syndrome.
Liver-Directed Treatment Shows Efficacy in Metabolic Dysfunction
A novel liver-directed treatment presented at endo 2026 offers a targeted approach for metabolic dysfunction, addressing a significant unmet clinical need.
Hypoparathyroidism Treatment: Patient, Care Partner, HCP Perspectives
New perspectives on hypoparathyroidism treatment from patients, care partners, and HCPs highlight unmet needs and treatment goals.
Severe Hypoglycemia in T1D: Enhancing Patient-Clinician Dialogue
Addressing severe hypoglycemic events in type 1 diabetes requires direct, empathetic clinician-patient conversations to improve management and outcomes.
Endocrinologists' Role in Early Thyroid Eye Disease Recognition
Early recognition of thyroid eye disease (TED) by endocrinologists is critical for optimal patient outcomes, enabling timely intervention.
Classic CAH: New Approaches to Glucocorticoid Dosing
Endocrinology specialists are re-evaluating glucocorticoid dosing strategies for classic congenital adrenal hyperplasia (CAH), focusing on individualised regimens to balance androgen control and minimise adverse effects.
Low Alkaline Phosphatase: Recognizing Clinical Consequences
Low alkaline phosphatase (ALP) is often overlooked, but its clinical consequences, particularly hypophosphatasia, warrant increased diagnostic vigilance.
Desmopressin Dosing Refined for Central Diabetes Insipidus
New insights into desmopressin administration for central diabetes insipidus (CDI) aim to optimise efficacy and minimise hyponatremia risk.
Acromegaly Management: Focus on Biochemical Control at ENDO 2026
New insights from ENDO 2026 highlight the persistent challenges in achieving biochemical control for acromegaly patients.
12 Months of Romosozumab Builds Bone Density in Postmenopausal Osteoporosis
A 12-month course of romosozumab significantly increases bone mineral density in postmenopausal women with osteoporosis.
Desiccated Thyroid Extract: Efficacy and Safety in Hypothyroidism
A case-based discussion at endo 2026 reviewed the role of desiccated thyroid extract (DTE) in hypothyroidism management, highlighting patient selection and comparative efficacy.
Steroidogenesis Inhibitor Targets Root Cause of Cushing’s Syndrome
A novel steroidogenesis inhibitor presented at ENDO 2026 offers a targeted approach to endogenous Cushing's syndrome by reducing cortisol overproduction.
Peer Insights on Once-Daily Weight Management Therapy at endo 2026
Endocrinology specialists discussed the clinical utility of a once-daily treatment for weight management in appropriate adult patients.
Hypothyroidism: Symptom Burden Persists Despite Euthyroidism
Many patients with hypothyroidism report persistent symptoms despite achieving biochemical euthyroidism, highlighting a significant symptom-treatment gap.
Endo 2026: Risk-Based Osteoporosis Management Refines Clinical Practice
Endo 2026 highlighted refined risk-based strategies for osteoporosis care, advocating for tailored interventions beyond universal guidelines to improve patient outcomes.
Hypercortisolism: Emerging Diagnostic and Management Insights
New evidence presented at Endo 2026 refines our understanding of hypercortisolism, impacting diagnostic strategies and therapeutic approaches.
Obesity Care: Tailored Treatment Strategies Highlighted at endo 2026
Personalised treatment approaches for obesity, moving beyond a 'one-size-fits-all' model, were a key focus at endo 2026.
Cushing's Syndrome: Addressing Diagnostic Delays and Treatment Gaps
Cushing's syndrome presents a diagnostic challenge, often leading to significant delays in treatment initiation and suboptimal patient outcomes.
Korlym® for Cushing's Syndrome: Patient Experience, Side Effects and 2026 Clinical Data
Patient-reported outcomes from Endo 2026 show Korlym® (mifepristone) cuts weight gain, fatigue and mood disturbances in Cushing's syndrome. Covers mechanism of cortisol receptor blockade, side effect profile, and how it compares to relacorilant.
XLH Adults: Osteomalacia Persists Despite Conventional Therapy
Adults with X-linked hypophosphatemia (XLH) frequently experience persistent osteomalacia, even with conventional phosphate and active vitamin D treatment.
Afirma Molecular Testing: Unique Situations and New Prognostic Development
Afirma molecular testing aids thyroid nodule management, particularly in indeterminate cytology. New prognostic markers enhance risk stratification.
GLP-1 RAs Reduce CV Risk in T2D Via Weight, Glucose Pathways
GLP-1 receptor agonists offer cardiovascular risk reduction in type 2 diabetes through both weight loss and direct glucose-lowering mechanisms.
Defining Hyperphagia Treatment Possibilities in Prader-Willi Syndrome
Clinician and caregiver perspectives highlight the complex challenges and unmet needs in managing hyperphagia in Prader-Willi Syndrome.
Liver-Directed Treatment Shows Efficacy in Metabolic Dysfunction
A novel liver-directed treatment presented at endo 2026 offers a targeted approach for metabolic dysfunction, addressing a significant unmet clinical need.
Hypoparathyroidism Treatment: Patient, Care Partner, HCP Perspectives
New perspectives on hypoparathyroidism treatment from patients, care partners, and HCPs highlight unmet needs and treatment goals.
Severe Hypoglycemia in T1D: Enhancing Patient-Clinician Dialogue
Addressing severe hypoglycemic events in type 1 diabetes requires direct, empathetic clinician-patient conversations to improve management and outcomes.
Endocrinologists' Role in Early Thyroid Eye Disease Recognition
Early recognition of thyroid eye disease (TED) by endocrinologists is critical for optimal patient outcomes, enabling timely intervention.
Classic CAH: New Approaches to Glucocorticoid Dosing
Endocrinology specialists are re-evaluating glucocorticoid dosing strategies for classic congenital adrenal hyperplasia (CAH), focusing on individualised regimens to balance androgen control and minimise adverse effects.
Low Alkaline Phosphatase: Recognizing Clinical Consequences
Low alkaline phosphatase (ALP) is often overlooked, but its clinical consequences, particularly hypophosphatasia, warrant increased diagnostic vigilance.
Desmopressin Dosing Refined for Central Diabetes Insipidus
New insights into desmopressin administration for central diabetes insipidus (CDI) aim to optimise efficacy and minimise hyponatremia risk.
Acromegaly Management: Focus on Biochemical Control at ENDO 2026
New insights from ENDO 2026 highlight the persistent challenges in achieving biochemical control for acromegaly patients.
12 Months of Romosozumab Builds Bone Density in Postmenopausal Osteoporosis
A 12-month course of romosozumab significantly increases bone mineral density in postmenopausal women with osteoporosis.
Desiccated Thyroid Extract: Efficacy and Safety in Hypothyroidism
A case-based discussion at endo 2026 reviewed the role of desiccated thyroid extract (DTE) in hypothyroidism management, highlighting patient selection and comparative efficacy.
Steroidogenesis Inhibitor Targets Root Cause of Cushing’s Syndrome
A novel steroidogenesis inhibitor presented at ENDO 2026 offers a targeted approach to endogenous Cushing's syndrome by reducing cortisol overproduction.
Peer Insights on Once-Daily Weight Management Therapy at endo 2026
Endocrinology specialists discussed the clinical utility of a once-daily treatment for weight management in appropriate adult patients.
Hypothyroidism: Symptom Burden Persists Despite Euthyroidism
Many patients with hypothyroidism report persistent symptoms despite achieving biochemical euthyroidism, highlighting a significant symptom-treatment gap.
Endo 2026: Risk-Based Osteoporosis Management Refines Clinical Practice
Endo 2026 highlighted refined risk-based strategies for osteoporosis care, advocating for tailored interventions beyond universal guidelines to improve patient outcomes.
Hypercortisolism: Emerging Diagnostic and Management Insights
New evidence presented at Endo 2026 refines our understanding of hypercortisolism, impacting diagnostic strategies and therapeutic approaches.
Obesity Care: Tailored Treatment Strategies Highlighted at endo 2026
Personalised treatment approaches for obesity, moving beyond a 'one-size-fits-all' model, were a key focus at endo 2026.
Cushing's Syndrome: Addressing Diagnostic Delays and Treatment Gaps
Cushing's syndrome presents a diagnostic challenge, often leading to significant delays in treatment initiation and suboptimal patient outcomes.
Korlym® for Cushing's Syndrome: Patient Experience, Side Effects and 2026 Clinical Data
Patient-reported outcomes from Endo 2026 show Korlym® (mifepristone) cuts weight gain, fatigue and mood disturbances in Cushing's syndrome. Covers mechanism of cortisol receptor blockade, side effect profile, and how it compares to relacorilant.
